Bayer recalls mislabeled vials of hemophilia treatment

By Maggie Lynch

- Last updated on GMT

(Image: Getty/youngvet)
(Image: Getty/youngvet)

Related tags Bayer Recall Label Manufacturing

Bayer recalls vials of an antihemophilic treatment after the discovery that nearly 1,000 were mislabeled with a therapy indicated for an adult patient population.

Bayer voluntarily recalls two lots of Kogenate FS antihemophilic factor 2000 IU vials (recombinant) in the US, as certain vials labeled as Kogenate FS actually contained Jivi antihemophilic factor PEGylated-aucl 3000 IU (recombinant), a FVIII hemophilia A treatment.

Kogenate FS and Jivi are both medicines used to replace clotting factor (factor VIII or antihemophilic factor) that is missing in people with hemophilia A.

Kogenate FS and Jivi are both approved to treat or control bleeding in patients with hemophilia A. However, Jivi is approved for previously treated adults 12 years or older with hemophilia A, and Kogenate FS is approved for children and adults.

Approximately 990 of the vials were released in the US and the recall is limited to this country, with Bayer stating that most of the mislabeled vials had been recovered.

The lots were distributed between February 5, 2019, and July 15, 2019.

Related news

Show more

Related products

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Fill-Finish Biologics

Fill-Finish Biologics

Curia | 16-May-2022 | Technical / White Paper

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for...

Follow us


View more